Company Description
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally.
The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.
Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers.
The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity.
The company was founded in 1998 and is headquartered in Andover, Massachusetts.
| Country | United States |
| Founded | 1998 |
| IPO Date | May 2, 2019 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 584 |
| CEO | Waleed Hassanein |
Contact Details
Address: 200 Minuteman Road, Suite 302 Andover, Massachusetts 01810 United States | |
| Phone | 978 552 0900 |
| Website | transmedics.com |
Stock Details
| Ticker Symbol | TMDX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001756262 |
| CUSIP Number | 89377M109 |
| ISIN Number | US89377M1099 |
| SIC Code | 3845 |
Key Executives
| Name | Position |
|---|---|
| Dr. Waleed H. Hassanein M.D. | Founder, President, Chief Executive Officer and Director |
| Nicholas Corcoran | Senior Vice President of Supply Chain and Operations |
| Anil Ranganath | Senior Vice President, General Counsel and Corporate Secretary |
| Dr. Tamer I. Khayal M.D. | Chief Commercial Officer |
| Gerardo Hernandez | Chief Financial Officer |
| Miriam C. Provost Ph.D. | Vice President of Global Regulatory Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 9, 2024 | 8-K | Current Report |
| Dec 6, 2024 | SCHEDULE 13G/A | Filing |
| Dec 2, 2024 | 8-K | Current Report |
| Nov 5, 2024 | 144 | Filing |
| Nov 1, 2024 | 144 | Filing |
| Oct 29, 2024 | 10-Q | Quarterly Report |
| Oct 28, 2024 | 8-K | Current Report |
| Oct 7, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Oct 7, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Oct 4, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |